SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
SVLSF VI, LLC	TRex Bio, Inc. [TRXB]	☐ Director ☑ 10% Owner
(Last) (First) (Middle)	Foreign Trading Symbol	☐ Officer (give title below) ☐ Other (specify below)
28 STATE STREET, SUITE 980	3. Date of Earliest Transaction (Month/Day/Year)	
(Street)	10/08/2026	
BOSTON MA 02109	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
(City) (State) (Zip)		☐ Form filed by One Reporting Person ☑ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/08/2026		P		89,783	A	$14	214,869	I	By SV Life Sciences Fund VI, L.P.(1)(5)
Common Stock	10/13/2026		C		1,574,074	A	$0	1,788,943	I	By SV Life Sciences Fund VI, L.P.(1)
Common Stock	10/13/2026		C		475,411	A	$0	2,264,354	I	By SV Life Sciences Fund VI, L.P.(1)
Common Stock	10/08/2026		P		3,074	A	$14	7,356	I	By SV Life Sciences Fund VI Strategic Partners, L.P. (2)(6)
Common Stock	10/13/2026		C		53,892	A	$0	61,248	I	By SV Life Sciences Fund VI Strategic Partners, L.P. (2)
Common Stock	10/13/2026		C		16,277	A	$0	77,525	I	By SV Life Sciences Fund VI Strategic Partners, L.P. (2)
Common Stock	10/13/2026		C		669,939	A	$0	669,939	I	By SV Trex Coinvestment, L.P.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(4)	10/13/2026		C			1,574,074	(4)	(4)	Common Stock	1,574,074	$0	0	I	By SV Life Sciences Fund VI, L.P.(1)
Series B Preferred Stock	(4)	10/13/2026		C			475,411	(4)	(4)	Common Stock	475,411	$0	0	I	By SV Life Sciences Fund VI, L.P.(1)
Series A Preferred Stock	(4)	10/13/2026		C			53,892	(4)	(4)	Common Stock	53,892	$0	0	I	By SV Life Sciences Fund VI Strategic Partners, L.P. (2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(4)	10/13/2026		C			16,277	(4)	(4)	Common Stock	16,277	$0	0	I	By SV Life Sciences Fund VI Strategic Partners, L.P. (2)
Series B Preferred Stock	(4)	10/13/2026		C			669,939	(4)	(4)	Common Stock	669,939	$0	0	I	By SV Trex Coinvestment, L.P.(3)

1. Name and Address of Reporting Person*

SVLSF VI, LLC

(Last) (First) (Middle)

28 STATE STREET, SUITE 980

(Street)

BOSTON MA 02109

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SV Life Sciences Fund VI (GP), L.P.

(Last) (First) (Middle)

28 STATE STREET, SUITE 980

(Street)

BOSTON MA 02109

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SV Life Sciences Fund VI, L.P.

(Last) (First) (Middle)

28 STATE STREET, SUITE 980

(Street)

BOSTON MA 02109

(City) (State) (Zip)

Explanation of Responses:

1. The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose.

2. The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose.

3. The shares are held directly by SV Trex Coinvestment, L.P. ("SV Coinvestment"). GP LP is the general partner of SV Coinvestment, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Coinvestment are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership and this report is not an admission of beneficial ownership for any other purpose.

4. On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date.

5. Represents shares purchased by SV Fund VI in the issuer's initial public offering.

6. Represents shares purchased by SV Strategic Partners VI in the issuer's initial public offering.

SVLSF VI, LLC By: Brent M. Faduski, Officer /s/ Brent M. Faduski	10/13/2026
SV Life Sciences Fund VI (GP), L.P. By: SVLSF VI, LLC, its General Partner By: Brent M. Faduski, Officer /s/ Brent M. Faduski	10/13/2026
SV Life Sciences Fund VI, L.P. By: SV Life Sciences Fund VI (GP), L.P., its General Partner By: SVLSF VI, LLC, its General Partner By: Brent M. Faduski, Officer /s/ Brent M. Faduski	10/13/2026
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.